Navigation Links
Marine bacteria to fight tough infections
Date:1/9/2014

Aggressive infections are a growing health problem all over the world. The development of resistant bacteria is rampant and, in the United States, resistant staphylococci cause more deaths than AIDS on an annual basis. Researchers from the University of Copenhagen are studying a new form of treatment based on marine bacteria. The results have been published in PLOS ONE.

Staphylococci have been a big problem for hospitals all over the world since the 1940s and, for many years, the pharmaceutical industry has been able to develop new antibiotics to keep up with the emergence of the aggressive bacteria. However, from 1970 to 2000, virtually no new antibiotics have come on the market. Staphylococci are gaining in the race resistance is growing, and treatment options are few. In short, doctors have been set back to the time before penicillin was mass produced.

Research performed in collaboration between the University of Copenhagen and the Technical University of Denmark (DTU) focus on a new form of treatment so-called antivirulence therapy based on marine bacteria producing Staphylococcus inhibiting compounds.

"The marine compounds effectively inhibit the ability of staphylococci to form toxins and camouflage proteins that prevent our immune system from reacting to an infection. At the same time, marine compounds appear to paralyse a sophisticated communication system that provides staphylococci the opportunity to undertake a coordinated attack on the organism," says Anita Nielsen, PhD. She has published new results in PLOS ONE with Professor Hanne Ingmer from the Department for Veterinary Disease Biology at the University of Copenhagen's Faculty of Health and Medical Sciences.

In the United States, resistant staphylococci cause more deaths than AIDS on an annual basis. Antivirulence therapy protects the body's natural bacterial flora and disarms, so to speak, infectious staphylococci bacteria. In this way, the body's immune system potentially gets a chance to defend itself against infection and, in the long term, this form of treatment can mean that patients experience fewer harmful side effects.

Potent compound from the Solomon Islands

The researchers have analysed compounds extracted from marine bacteria collected from all over the world on the Galathea 3 expedition, which took place from August 2006 until April 2007. One particular compound, Solonamid B, isolated from a marine bacterium found near the Solomon Islands, is of particular interest.

"Solonamid B inhibits the ability of staphylococci to produce various toxins that break down our blood cells. White blood cells in particular are important in this context, because they participate in the fight against invasive bacteria during an infection. When Solonamid B is added to bacteria, it reduces their toxin production so only a fifth of the white blood cells die that would otherwise succumb to the staphylococci toxins," says Professor Hanne Ingmer.

It has required demanding laboratory work to analyse the compounds that can form the basis for antivirulence therapy in the future. Purification and identification of the Solonamid B used for the cell studies were undertaken in collaboration with DTU. Researchers at DTU extracted the compounds that researchers at University of Copenhagen subsequently tested biologically. Future experiments will show whether the antivirulence compounds also work in animals and human beings.


'/>"/>

Contact: Hanne Ingmer
hi@sund.ku.dk
45-22-15-95-18
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Major reductions in seafloor marine life from climate change by 2100
2. DNA barcoding to monitor marine mammal genetic diversity
3. New study reveals the biomechanics of how marine snail larvae swim
4. Marine biologists unmask species diversity in coral reefs
5. The big unknown: Factoring marine sediments into climate calculations
6. Arctic study shows key marine food web species at risk from increasing CO2
7. Microplastics make marine worms sick
8. Marine reserves enhance resilience to climate change
9. Stingray movement could inspire the next generation of submarines
10. Assessing noise impact of offshore wind farm construction may help protect marine mammals
11. NOAA awards $967,000 to 11 marine debris removal projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology: